By 2030, chronic subdural haemorrhage will be the most common adult brain condition requiring neurosurgical intervention in the USA, according to a new study conducted by researchers at NYU Langone Medical Center, USA, and hospitals and neurosurgeons may be under-manned to handle the projected onslaught of patients.
IMRIS Inc has announced that VISIUS iCT, the first and only ceiling-mounted intraoperative computed tomography scanner, has received Health Canada licensing allowing for sales and marketing in the country.
Three prominent neurosurgeons will review their clinical experience using real-time navigated laser therapy for brain lesion ablation within intraoperative MRI suites at the upcoming 83rd American Association of Neurological Surgeons (AANS) Annual Scientific Meeting (2-6 May, Washington, DC, USA). IMRIS, MRI Interventions, and Monteris Medical jointly announced that the companies are sponsoring the Lunch and Learn seminar scheduled for on Monday, 4 May.
Medtronic plc has announced that it has received clearance from the US Food and Drug Administration (FDA) for expanded indications of specific StealthStation electromagnetic surgical navigation system instruments for paediatric and adult cranial and ENT procedures.
Cefaly Technology, the creators of the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorised for use prior to the onset of migraine pain, is set to announce significant breakthroughs in migraine treatment at the EUROHEADPAIN Midterm Meeting at the International Headache Society Congress in Valencia, Spain, from 14–17 May, 2015.
DUBLIN--(Healthcare Sales & Marketing Network)-- Two global trials published online in The New England Journal of Medicine (NEJM) and presented at the European Stroke Organisation Conference found that the addition of the Solitaire™ device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke. These trials confirmed the findings of three previous trials also published in NEJM.
Due to their unique characteristics, flow diverters were originally intended to provide a reconstructive treatment option for atypical cerebral aneurysms which previously had no feasible management alternatives, failed prior therapy, or conventional endovascular methods (coiling, stent-assisted coiling, balloon-assisted coiling, liquid embolic agents) showed suboptimal results or increased recurrence. These devices are metal mesh tubes, which on first glance may resemble conventional stents. However, significant differences are noted in that they have higher surface metal coverage and lower porosity than previously available vascular reconstruction devices.
The publication and presentation of four endovascular trials for acute ischaemic stroke has evoked a number of metaphors: “sea change”, “new day”, and “the polar vortex has lifted”. But there is an overwhelming consensus that we have taken a big step forward in acute ischaemic stroke therapy. The trial which opened the floodgates was the MR CLEAN trial (Multicentre randomized clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands) which presented its results in October at the World Stroke Congress. These clearly positive data prompted the data and safety monitoring boards of other ongoing endovascular trials to review their own data. All of these trials were then stopped early because of clear efficacy and crossing of stopping boundaries within the respective trials. And this is the reason why so many positive trials were presented simultaneously at the International Stroke Conference in Nashville, USA this February – something we may never see again at a single international stroke meeting.
In a post-hoc analysis of the use of general anaesthesia in the MR CLEAN trial (Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands) investigators have found that the subgroup of patients treated without general anaesthesia benefited more from the endovascular treatment than the subgroup treated under general anaesthesia.
People with haemorrhagic strokes are more likely to survive if they are treated at a comprehensive stroke centre, according to research published in the Journal of the American Heart Association.
Codman Neuro has launched the Enterprise 2 vascular reconstruction device in Europe. The Enterprise 2 system is the latest generation of the company’s self-expanding stent and delivery system used to treat wide-necked intracranial aneurysms and to help maintain the position of endovascular coils. Codman Neuro is a part of the DePuy Synthes Companies of Johnson & Johnson.
Air pollution, even at moderate levels, has long been recognised as a factor in raising the risk of stroke. A new study led by scientists from Beth Israel Deaconess Medical Center and Boston University School of Medicine, USA, suggests that long-term exposure can cause damage to brain structures and impair cognitive function in middle-aged and older adults.
Interventional treatments—especially surgery—provide good functional outcomes and a high cure rate for patients with lower-grade arteriovenous malformations (AVMs) of the brain, reports the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Use of either proximal embolic protection devices (P-EPDs) or distal filter embolic protection devices (F-EPDs) during elective carotid artery stenting results in low rates of in-hospital stroke and death, according to a new study from researchers at the Perelman School of Medicine at the University of Pennsylvania, USA.
Silk Road Medical has announced the first US commercial procedure using the Enroute transcarotid neuroprotection system was successfully performed at Mills-Peninsula Medical Center in Burlingame, USA by vascular surgeon John E Rosenman.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos